Imfinzi plus chemotherapy approved in the EU as first immunotherapy regimen for patients with advanced biliary tract cancer January 4, 2023
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers January 4, 2023
Imfinzi plus chemotherapy recommended for approval in the EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer November 23, 2022
Imfinzi + chemo further improved OS benefit in advanced biliary tract cancer in the TOPAZ-1 Ph 3 trial, reducing the risk of death by 24% in additional follow-up September 13, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer September 13, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced BTC September 7, 2022
EMA Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer June 14, 2022
